JP2019524897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524897A5 JP2019524897A5 JP2019531546A JP2019531546A JP2019524897A5 JP 2019524897 A5 JP2019524897 A5 JP 2019524897A5 JP 2019531546 A JP2019531546 A JP 2019531546A JP 2019531546 A JP2019531546 A JP 2019531546A JP 2019524897 A5 JP2019524897 A5 JP 2019524897A5
- Authority
- JP
- Japan
- Prior art keywords
- dystonia
- subject
- pridopidine
- primary
- systemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000014094 Dystonic disease Diseases 0.000 claims 55
- 208000010118 dystonia Diseases 0.000 claims 49
- 238000000034 method Methods 0.000 claims 28
- 230000009885 systemic effect Effects 0.000 claims 7
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims 6
- 229950003764 pridopidine Drugs 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims 2
- 208000013454 early-onset generalized dystonia Diseases 0.000 claims 2
- 230000006872 improvement Effects 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000002899 segmental dystonia Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 1
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical group Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 241000173529 Aconitum napellus Species 0.000 claims 1
- 241000567030 Ampulloclitocybe clavipes Species 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- 101000662686 Homo sapiens Torsin-1A Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000011093 Myoclonus-dystonia syndrome Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 206010043101 Talipes Diseases 0.000 claims 1
- 102100037454 Torsin-1A Human genes 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000013142 Writer cramp Diseases 0.000 claims 1
- 201000003426 X-linked dystonia-parkinsonism Diseases 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 229940023019 aconite Drugs 0.000 claims 1
- 230000009471 action Effects 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 229930016911 cinnamic acid Natural products 0.000 claims 1
- 235000013985 cinnamic acid Nutrition 0.000 claims 1
- 201000011228 clubfoot Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 claims 1
- 201000002865 focal hand dystonia Diseases 0.000 claims 1
- 229940044170 formate Drugs 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 1
- 230000004118 muscle contraction Effects 0.000 claims 1
- 201000003346 myoclonic dystonia Diseases 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 201000001340 torsion dystonia 1 Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078788A JP7278327B2 (ja) | 2016-08-24 | 2021-05-06 | ジストニアを治療するためのプリドピジンの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379175P | 2016-08-24 | 2016-08-24 | |
| US62/379,175 | 2016-08-24 | ||
| US201662395319P | 2016-09-15 | 2016-09-15 | |
| US62/395,319 | 2016-09-15 | ||
| PCT/US2017/048458 WO2018039475A1 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating dystonias |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078788A Division JP7278327B2 (ja) | 2016-08-24 | 2021-05-06 | ジストニアを治療するためのプリドピジンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524897A JP2019524897A (ja) | 2019-09-05 |
| JP2019524897A5 true JP2019524897A5 (enExample) | 2019-10-17 |
| JP7278210B2 JP7278210B2 (ja) | 2023-05-19 |
Family
ID=61246309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531546A Active JP7278210B2 (ja) | 2016-08-24 | 2017-08-24 | ジストニアを治療するためのプリドピジンの使用 |
| JP2021078788A Active JP7278327B2 (ja) | 2016-08-24 | 2021-05-06 | ジストニアを治療するためのプリドピジンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078788A Active JP7278327B2 (ja) | 2016-08-24 | 2021-05-06 | ジストニアを治療するためのプリドピジンの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11826361B2 (enExample) |
| EP (1) | EP3503890B1 (enExample) |
| JP (2) | JP7278210B2 (enExample) |
| CN (1) | CN110012661A (enExample) |
| AU (1) | AU2017315781B2 (enExample) |
| BR (1) | BR112019003731A2 (enExample) |
| CA (1) | CA3035099C (enExample) |
| DK (1) | DK3503890T3 (enExample) |
| ES (1) | ES3009437T3 (enExample) |
| MX (1) | MX2019002190A (enExample) |
| PL (1) | PL3503890T3 (enExample) |
| WO (1) | WO2018039475A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011298382A1 (en) | 2010-09-03 | 2013-05-02 | Teva Pharmaceuticals International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| KR102316933B1 (ko) | 2013-06-21 | 2021-10-26 | 프리레니아 뉴로테라퓨틱스 엘티디. | 헌팅턴병 치료를 위한 프리도피딘의 용도 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| CA3176917A1 (en) * | 2020-05-04 | 2021-11-11 | Prilenia Neurotherapeutics Ltd. | Treatment of viral infection, disease or disorder using a selective s1r agonist |
| WO2024142058A1 (en) * | 2022-12-27 | 2024-07-04 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating juvenile huntington's disease |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
| US20250281500A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| AU2005251909A1 (en) * | 2004-06-08 | 2005-12-22 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| SE0401465D0 (sv) * | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| AU2005293754B2 (en) | 2004-10-13 | 2011-07-21 | Teva Pharmaceuticals International Gmbh | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| DK2146961T3 (da) | 2007-04-12 | 2014-04-28 | Ivax Int Gmbh | N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler |
| US8562488B2 (en) * | 2009-10-05 | 2013-10-22 | The Cleveland Clinic Foundation | Systems and methods for improving motor function with assisted exercise |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| AU2011298382A1 (en) | 2010-09-03 | 2013-05-02 | Teva Pharmaceuticals International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| KR20140075703A (ko) | 2011-09-07 | 2014-06-19 | 아이백스 인터내셔널 게엠베하 | 프리도피딘 하이드로클로라이드의 다형 형태 |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| US20140037850A1 (en) * | 2012-08-06 | 2014-02-06 | General Electric Company | Corrosion and wear resistant organic coatings |
| KR102316933B1 (ko) * | 2013-06-21 | 2021-10-26 | 프리레니아 뉴로테라퓨틱스 엘티디. | 헌팅턴병 치료를 위한 프리도피딘의 용도 |
| DK3096759T3 (da) | 2014-01-22 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Pridopidinformuleringer med modificeret frigivelse |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| JP2018505147A (ja) | 2014-12-22 | 2018-02-22 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジンのｌ−酒石酸塩 |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| WO2017015615A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| AU2017223838B2 (en) | 2016-02-24 | 2022-09-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
| US20200375966A1 (en) | 2016-09-15 | 2020-12-03 | Prilenia Therapeutics Development Ltd | Use of pridopidine for the treatment of anxiety and depression |
| AU2017326013B2 (en) | 2016-09-16 | 2020-12-24 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating Rett syndrome |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| HUE068300T2 (hu) | 2017-01-20 | 2024-12-28 | Prilenia Neurotherapeutics Ltd | Pridopidin törékeny X szindróma kezelésében történõ alkalmazásra |
| BR112020003119A2 (pt) | 2017-08-14 | 2020-10-13 | Prilenia Neurotherapeutics Ltd. | método de tratamento de esclerose lateral amiotrófica com pridopidina |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
-
2017
- 2017-08-24 MX MX2019002190A patent/MX2019002190A/es unknown
- 2017-08-24 ES ES17844432T patent/ES3009437T3/es active Active
- 2017-08-24 DK DK17844432.9T patent/DK3503890T3/da active
- 2017-08-24 EP EP17844432.9A patent/EP3503890B1/en active Active
- 2017-08-24 CA CA3035099A patent/CA3035099C/en active Active
- 2017-08-24 CN CN201780066796.2A patent/CN110012661A/zh active Pending
- 2017-08-24 BR BR112019003731A patent/BR112019003731A2/pt not_active IP Right Cessation
- 2017-08-24 JP JP2019531546A patent/JP7278210B2/ja active Active
- 2017-08-24 AU AU2017315781A patent/AU2017315781B2/en active Active
- 2017-08-24 PL PL17844432.9T patent/PL3503890T3/pl unknown
- 2017-08-24 WO PCT/US2017/048458 patent/WO2018039475A1/en not_active Ceased
-
2019
- 2019-02-24 US US16/283,784 patent/US11826361B2/en active Active
-
2021
- 2021-05-06 JP JP2021078788A patent/JP7278327B2/ja active Active
-
2023
- 2023-10-19 US US18/489,846 patent/US20240075021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524897A5 (enExample) | ||
| JP6445637B2 (ja) | うつ病および不安を予防し治療するためのタペンタドール | |
| US11590107B2 (en) | Methods for treating neurological disorders with α1A-AR partial agonists | |
| CN113271936A (zh) | 治疗神经和精神疾病的方法 | |
| US11738002B2 (en) | Methods of treating neurological and psychiatric disorders | |
| JP2022105159A (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| JP2019532926A5 (enExample) | ||
| JP2012197304A (ja) | ミオパシー関連性の覚醒障害を矯正することが意図される医薬品を製造するためのモダフィニルの使用 | |
| KR102549684B1 (ko) | 신경퇴행성 질병에 대한 치료제 | |
| Wernicke et al. | Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP) | |
| JP5908072B2 (ja) | 腹圧性尿失禁予防剤及び／又は治療剤 | |
| RU2014126070A (ru) | Способы лечения и предотвращения глазных заболеваний | |
| CN109310669A (zh) | 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 | |
| JP4972156B2 (ja) | ＶＩ型コラーゲン欠損に起因する先天性筋ジストロフィーまたはミオパシーの予防および／または処置のためのＮ−（ジベンゾ（ｂ，ｆ）オキセピン−１０−イルメチル）Ｎ−メチル−Ｎ−プロプ−２−イニルアミン（オミガピル）の使用法 | |
| JP7744419B2 (ja) | レット症候群を治療するためのプリドピジンまたはその類似体の使用 | |
| WO2015149706A1 (zh) | 芬戈莫德及其结构类似物用于制备治疗脑出血药物的应用 | |
| KR102900174B1 (ko) | 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
| WO2025162430A1 (zh) | 一种药物联用及其在预防或治疗神经退行性疾病中的用途 | |
| WO2025181805A1 (en) | Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof | |
| Thu-Thuy et al. | Long-term follow-up of notched T waves in female patients with LQT2 (HERG) mutations | |
| Fry et al. | Laminectomy for postsyphilitic nerve root pain | |
| JP2020527168A (ja) | アザピロン系化合物の副交感神経の機能向上の使用 | |
| HK1230925A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| JPWO2014088106A1 (ja) | 線維筋痛症の予防または治療薬 |